Key Highlights
- RHHBY shares advanced 1.18% following third-quarter revenue expansion of 7% at constant currency.
- Nine-month group revenue reached CHF 46.5 billion, driven by flagship pharmaceutical products.
- US regulators cleared Tecentriq and Enspryng for expanded therapeutic indications.
- Five leading medicines contributed CHF 16.8 billion, posting 12% constant-currency expansion.
- Full-year 2026 growth projections remain unchanged following diagnostic and pharmaceutical advances.
Shares of Roche Holding AG (RHHBY) rose 1.18% to close at $59.81, adding $0.70 in value as investors responded to the company’s latest financial results. The Basel-based biopharmaceutical giant posted quarterly revenue growth of 7% when measured at constant exchange rates, while announcing multiple US regulatory clearances. Demand for its leading therapies and advancement across clinical programs further bolstered investor confidence.
Pharmaceutical Division Drives Revenue Performance
The pharmaceutical company delivered CHF 46.5 billion in consolidated revenue across the initial nine months of 2026, marking a 6% increase at constant currency. Currency headwinds stemming from the stronger Swiss franc compressed reported growth to 1%, though underlying demand for therapies and diagnostic solutions remained solid. During the third quarter alone, sales climbed 8% in Swiss franc terms as exchange rate challenges moderated.
The Pharmaceuticals business segment posted CHF 36.2 billion in revenue, achieving 7% growth when adjusted for currency fluctuations. Five cornerstone products—Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo—collectively generated CHF 16.8 billion. This group of therapies registered 12% constant-currency growth, strengthening performance across oncology, ophthalmology, and hematology franchises.
Geographic performance varied across Roche’s global footprint. Japanese markets surged 25% at constant currency, while international territories posted 10% growth and US operations expanded 5%. Established medicines experienced revenue pressure from biosimilar competition, offsetting gains from newer product launches and indication expansions.
US Regulatory Wins Expand Treatment Offerings
Roche obtained multiple clearances from US health authorities during recent months, broadening its therapeutic reach in oncology and inflammatory conditions. Regulators approved Tecentriq in combination with chemotherapy for specific stage III colon cancer patients following surgical resection. Trial data demonstrated the regimen cut the risk of disease recurrence or death in half versus chemotherapy alone.
Enspryng received approval for thyroid eye disease, offering patients an alternative to infusion-based therapy through self-administered treatment. The company also obtained Priority Review designation for fenebrutinib in both relapsing and primary progressive forms of multiple sclerosis. Late-stage studies revealed fenebrutinib lowered relapse frequency by 51% and 58% when compared with teriflunomide.
Clinical development milestones extended across renal disease, oncology, metabolic disorders, and weight management programs. The investigational diabetes medication enicepatide produced mean body weight reduction of 15.5% at the maximum tested dose following 48 weeks of treatment. The organization aims to introduce as many as 20 novel therapies before the close of 2030.
Diagnostics Progress and Financial Guidance Reinforce Growth Trajectory
The Diagnostics Division contributed CHF 10.3 billion in nine-month revenue, posting 4% constant-currency advancement. Robust laboratory and pathology product demand balanced pricing adjustments implemented in Chinese markets. North American operations grew 9%, while Latin American territories expanded 12% on a constant-currency basis.
US regulators also authorized Roche’s Elecsys pTau217 assay for FDA-cleared Alzheimer’s disease evaluation. The blood-based test enables physicians to detect amyloid pathology using a single biomarker across primary care and specialty settings. The company intends to leverage its established US laboratory infrastructure to facilitate broader test availability.
Management reaffirmed its 2026 financial projections following third-quarter results and recent regulatory achievements. The firm anticipates mid-single-digit consolidated sales growth alongside high-single-digit core earnings-per-share expansion at constant exchange rates. Plans include another Swiss franc dividend increase while advancing manufacturing capacity and research facilities within the United States.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
